NeurAxis Looks To Revolutionize The Treatment Of Adolescent Stomach Issues

NeurAxis, Inc. NRXS looks to revolutionize how pediatric irritable bowel syndrome (IBS) and functional abdominal pain (FAP) are treated.  

Right now, both are “associated with recurrent abdominal pain and are among the most commonly diagnosed medical problems in pediatrics,” says Therapy. To treat it, many companies – and physicians will use potent prescription pharmaceuticals, off-label. 

However, that’s not always a safe route.

NeurAxis, on the other hand, is providing a drug-free alternative. 

Called IB-Stim, it’s the “first device or drug therapy approved by the US Food and Drug Administration (FDA) for adolescents with functional pain associated with Irritable Bowel Syndrome,” according to KidStomachPain.com. 

“Stimulating the nerves through your ear can change the activity of the amygdala and the vagus nerve, two areas of the brain that are involved in processing pain. That’s what IB-Stim does. It’s the only device that stimulates both simultaneously. Studies have shown that IB-Stim decreased activity in the amygdala by as much as 50%,” they added.

In short, that stimulation targets brain areas involved in processing pain and aids in the reduction of functional abdominal pain associated with Irritable Bowel Syndrome.

Better, current success could earn the company a “front-line treatment” designation, which could significantly change treatment options. It could even give NeurAxis NRXS a much bigger piece of a $9 billion addressable pediatric care market.

For an idea of how big the addressable markets are, consider this.

At some point, according to ChildrensHospital.org, “10 percent to 15 percent of children have IBS at some point.” Also, according to UptoDate.com, “Functional abdominal pain disorders (FAPDs) are considered the result of abnormal interactions between the gut and the brain. FAPDs are the most common cause of chronic abdominal pain in children and adolescents, occurring in 9 to 15 percent of all children. In males, pain is most common between ages 5 and 6 years. Females have pain most commonly between 5 and 6 years and 9 and 10 years.”

If NeurAxis NRXS sees further success, it could revolutionize the treatment industry, and be a game-changer for the IRXS stock.

Learn more about NeurAxis Inc. NRXS here.

Image sourced from Shutterstock

This post was authored by an external contributor and does not represent Benzinga's opinions and has not been edited for content. This contains sponsored content and is for informational purposes only and not intended to be investing advice.